par Majewski, Ian IJ;Nuciforo, Paolo;Mittempergher, Lorenza;Bosma, Astrid AJ;Eidtmann, Holger;Holmes, Eileen;Sotiriou, Christos 
;Fumagalli, Debora ;Jimenez, Jose;Aura, Claudia;Prudkin, Ljudmila;Díaz-Delgado, Maria Carmen;de la Peña, Lorena;Loi, Sherene ;Ellis, Catherine;Schultz, Nikolaus;de Azambuja, Evandro ;Harbeck, Nadia;Piccart-Gebhart, Martine ;Bernards, René;Baselga, José
Référence Journal of clinical oncology
Publication Publié, 2015-01
;Fumagalli, Debora ;Jimenez, Jose;Aura, Claudia;Prudkin, Ljudmila;Díaz-Delgado, Maria Carmen;de la Peña, Lorena;Loi, Sherene ;Ellis, Catherine;Schultz, Nikolaus;de Azambuja, Evandro ;Harbeck, Nadia;Piccart-Gebhart, Martine ;Bernards, René;Baselga, JoséRéférence Journal of clinical oncology
Publication Publié, 2015-01
Article révisé par les pairs
| Résumé : | We investigated whether mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) correlates with response to neoadjuvant human epidermal growth factor receptor 2 (HER2) -targeted therapies in patients with breast cancer. |
